Palisade BioPalisade Bio terminates its post-surgical abdominal adhesions treatment trial

10 Aug 2023
www.pharmaceutical-technology.com
Phase 2Financial Statement
Palisade Bio terminates its post-surgical abdominal adhesions treatment trial
Preview
Source: Pharmaceutical Technology
Phalguni Deswal
@Phalguni_GD
Palisade Bio terminates its post-surgical abdominal adhesions treatment trial
Preview
Source: Pharmaceutical Technology
Tranexamic acid is also under development for post-operative ileus, and accelerating the return of bowel function post-abdominal surgery. Image Credit: Buravleva stock / Shutterstock.
Palisade Bio has terminated the development of its lead clinical candidate, tranexamic acid (LB1148), for reducing intra-abdominal adhesions in patients after elective bowel resection surgery.
The news led to a sharp 69% decline in Palisade’s stock at market open on 9 August, compared to market close on the previous day. The company’s market cap stands at $4.8m.
Recommended Reports
Palisade Bio terminates its post-surgical abdominal adhesions treatment trial
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Rezvilutamide in Liver Failure (Hepatic Insufficiency) GlobalData
Palisade Bio terminates its post-surgical abdominal adhesions treatment trial
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Aramchol in Liver Failure (Hepatic Insufficiency) GlobalData
View allCompanies IntelligencePalisade Bio, IncPalisade CorpView all
Tranexamic acid is a broad-spectrum serum protease inhibitorserum protease inhibitor. It reduces damage to the intestine by neutralising digestive enzymes.
The drug was investigated for the indication in a randomised, placebo-controlled, multicentre Phase II clinical trial (NCT02836470) that failed to meet its primary endpoint. Furthermore, 16 serious adverse events were observed in the tranexamic acid group, compared to 14 events in the placebo group, as per the press release.
The clinical trial was wrought with difficulties. It was paused in July 2020 due to Covid-19, leading to low patient recruitment. After its restart in May 2022, the study’s protocol was changed to investigate the use of LB1148 in reducing adhesions from its original indication of the return of gastrointestinal function in patients post-elective bowel resection surgery.
Tranexamic acid is also under development for post-operative ileus and accelerating the return of bowel function post-abdominal surgery.
PalisadePalisade has a development and licencing agreement with Newsora for the tranexamic acid programme in China. The agreement grants PalisadePalisade clinical, regulatory, and commercial milestone-based payments, as well as tiered royalty payments for net annual sales in greater China.
PalisadePalisade reduced its workforce by 30% at the start of 2023, as part of a cost-reduction strategy. As per the company’s 2022 financial report, it has cash reserves of $12.4m to fund its operation to mid-2024.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.